OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy	824
Cancer metabolism: looking forward	683
Targeting ferroptosis as a vulnerability in cancer	656
Therapeutic cancer vaccines	639
RNA in cancer	631
Role of RNA modifications in cancer	605
Systemic immunity in cancer	600
A compendium of mutational cancer driver genes	589
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion	545
Neutrophil diversity and plasticity in tumour progression and therapy	530
Connecting copper and cancer: from transition metal signalling to metalloplasia	511
Endoplasmic reticulum stress signals in the tumour and its microenvironment	503
The role of ROS in tumour development and progression	467
The rediscovery of platinum-based cancer therapy	445
The matrix in cancer	441
Recent advances and discoveries in the mechanisms and functions of CAR T cells	436
The metabolism of cancer cells during metastasis	425
p53: 800 million years of evolution and 40 years of discovery	412
Metabolism of immune cells in cancer	401
Key steps for effective breast cancer prevention	372
Long noncoding RNAs in cancer metastasis	332
Interleukins in cancer: from biology to therapy	321
Advances in bladder cancer biology and therapy	308
The cancer–natural killer cell immunity cycle	305
The evolving translational potential of small extracellular vesicles in cancer	296

The dormant cancer cell life cycle	285
Non-genetic mechanisms of therapeutic resistance in cancer	285
Linking EMT programmes to normal and neoplastic epithelial stem cells	270
Exploiting senescence for the treatment of cancer	261
Advancing targeted protein degradation for cancer therapy	246
Cancer stem cell–immune cell crosstalk in tumour progression	235
Mutations and mechanisms of WNT pathway tumour suppressors in cancer	223
The immunological and metabolic landscape in primary and metastatic liver cancer	215
Natural killer cells in antitumour adoptive cell immunotherapy	213
Cancer progression and the invisible phase of metastatic colonization	194
Autophagy in tumour immunity and therapy	187
Designing deep learning studies in cancer diagnostics	176
The language of chromatin modification in human cancers	174
Harnessing multimodal data integration to advance precision oncology	170
Targeting DNA damage response pathways in cancer	167
Tumour fatty acid metabolism in the context of therapy resistance and obesity	166
A new dawn for eosinophils in the tumour microenvironment	158
CRISPR in cancer biology and therapy	157
Genetic and non-genetic clonal diversity in cancer evolution	150
Targeting the DNA damage response in immuno-oncology: developments and opportunities	149
Targeting FAK in anticancer combination therapies	149
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs	144
Antitumour immunity regulated by aberrant ERBB family signalling	139
Cancer nanomedicine	137
Zebrafish patient avatars in cancer biology and precision cancer therapy	134
Sex disparities matter in cancer development and therapy	134
MYC protein interactors in gene transcription and cancer	134
Targeting CDK4 and CDK6 in cancer	130
Programmed death ligand 1 signals in cancer cells	130
Mutational signatures: emerging concepts, caveats and clinical applications	128
Clonal expansion in non-cancer tissues	128
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance	123
Overcoming TGFβ-mediated immune evasion in cancer	122
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data	121
Hyperinsulinaemia in cancer	119
Liquid–liquid phase separation drives cellular function and dysfunction in cancer	119
The epigenomics of sarcoma	119
2-Oxoglutarate-dependent dioxygenases in cancer	117
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities	113
Prostate carcinogenesis: inflammatory storms	112
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer	108
Stress and cancer: mechanisms, significance and future directions	104
Improving human cancer therapy through the evaluation of pet dogs	102
Aneuploidy as a promoter and suppressor of malignant growth	99
Mechanisms of immune activation and regulation: lessons from melanoma	99
The plasticity of mRNA translation during cancer progression and therapy resistance	99
Mitochondrial DNA variation and cancer	98
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment	96
Advances in germline predisposition to acute leukaemias and myeloid neoplasms	91
Tumour predisposition and cancer syndromes as models to study gene–environment interactions	91

Polyamines in cancer: integrating organismal metabolism and antitumour immunity	90
Artificial intelligence in cancer research, diagnosis and therapy	88
A timeline of tumour-associated macrophage biology	86
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis	84
Glial and myeloid heterogeneity in the brain tumour microenvironment	83
Synthetic biomarkers: a twenty-first century path to early cancer detection	82
Cancer proteogenomics: current impact and future prospects	82
RNA splicing dysregulation and the hallmarks of cancer	78
Decoding leader cells in collective cancer invasion	77
Mapping the genomic diaspora of gastric cancer	72
Peripheral T cell lymphomas: from the bench to the clinic	72
Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention	70
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies	69
Big data in basic and translational cancer research	69
Leukaemia: a model metastatic disease	69
Metabolic rivalry: circadian homeostasis and tumorigenesis	64
Targeting the gut microbiota for cancer therapy	63
Emerging themes in cohesin cancer biology	63
mRNA-based cancer therapeutics	60
Biology, vulnerabilities and clinical applications of circulating tumour cells	60
Non-coding driver mutations in human cancer	57
Targeting transcription cycles in cancer	56
Developing dietary interventions as therapy for cancer	55
Dynamics and specificities of T cells in cancer immunotherapy	53
The coming decade in precision oncology: six riddles	52
STAT proteins in cancer: orchestration of metabolism	50
Therapeutic targeting of tumour myeloid cells	50
Tissue clearing to examine tumour complexity in three dimensions	49
Evolving cancer–niche interactions and therapeutic targets during bone metastasis	49
Nucleotide metabolism: a pan-cancer metabolic dependency	47
Acetyl-CoA metabolism in cancer	47